Business Context and Reporting Period
This Form 8-K Current Report from Bone Biologics Corp (Delaware corporation) covers the Annual Meeting of Stockholders held on June 5, 2017. The report details the voting results for director elections and executive compensation approval.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events rather than financial performance.
Material Changes
No material financial changes are reported in this document. The primary event is the successful ratification of the Board of Directors and executive compensation by the stockholders.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the outcomes of the shareholder vote.
Important Facts for Investors
- Director Election: Stockholders approved the election of Stephen LaNeve, Bruce Stroever, John Booth, and Jimmy Delshad to the Board of Directors with 33,786,265 "FOR" votes and 0 "WITHHELD" votes.
- Executive Compensation: The advisory vote on executive compensation was approved with 31,844,792 "FOR" votes against 1,941,473 "AGAINST" votes.
- Shareholder Participation: There were 5,042,342 "NON VOTES" recorded for the director election proposal.
- Emerging Growth Status: The company is identified as an emerging growth company.